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Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system \[[@CR1]\]. The disease most often begins between the second and fourth decade of life, but it can also begin later, as well as in childhood. In recent years, MS is increasingly recognized in the pediatric population \[[@CR2]\], in which clinical findings, magnetic resonance imaging (MRI), and laboratory analyses may vary significantly as compared to the adult population \[[@CR3]\]. Therefore, new and emerging research in the field of pediatric MS is of crucial importance for both the early and correct diagnosis of pediatric MS, as well as its treatment. The first clinical and pathological description of MS was given by Prof. Jean-Martin Charcot in the nineteenth century, naming it *sclerose en plaques* \[[@CR4]\]. A more intensive study of the etiology and pathophysiological processes underlying MS began before World War II, when an autoimmune theory was proposed, later followed by the discovery of the genetic basis of the disease \[[@CR5]--[@CR7]\]. The implementation of immunomodulatory therapy took place in the early nineties and it still is the first line of treatment in MS patients \[[@CR5]\].

One of the main characteristics of MS is its geographic distribution \[[@CR8]\], which is best illustrated by the fact that 50 percent of all MS patients are from Europe \[[@CR9]\]. Results of different studies indicate an increase in the number of patients with MS since 1985, especially among women \[[@CR9]\], although this can be partially explained by rapid advances in making the diagnosis of MS during recent decades. The assumption is that 2.3 million people in the world have MS \[[@CR10]\], while 2.7--10.5 % of all MS cases represent patients younger than 18 years of age \[[@CR2]\]. Epidemiological studies indicate that there are areas with a high prevalence of MS (\>30/100,000) such as some northern Europe countries and North America, and areas with a low prevalence of MS (\<5/100,000) such as Africa, China, Japan, Latin and South America \[[@CR9], [@CR11]\]. Sardinia is the place with the highest prevalence of the pediatric MS in the world \[[@CR12]\]; however, the area with the highest prevalence of 300 per 100,000 is the Orkney Islands, including both adult and pediatric MS \[[@CR8]\]. If we observe the American continent, MS is most common in non-Hispanic white individuals. Furthermore, in the last few years, pediatric MS becomes more common in African Americans than adult MS in the same population. African Americans have more severe clinical presentation compared to the white population if the disease starts early \[[@CR13]\]. In the United States, the prevalence varies from 58 to 95 per 100,000. In pediatric hospitals in Canada, MS is increasingly diagnosed in ethnic populations, such as Caribbean, Asian, central and eastern European \[[@CR14]\], more likely caused by genetics, environmental factors, infections, as well as inadequate exposure to sunlight, and consequently vitamin D deficiency. Namely, vitamin D deficiency or a polymorphism of vitamin D receptor gene diminishes its optimal function on the immune system that consequently could lead to increasing risk of MS \[[@CR15]\]. However, its role in development and modulating the course of MS remains to be further elucidated.

Pediatric MS is usually diagnosed around 15 years of age \[[@CR16]\], but one should be aware of its incidence in even younger children. Early onset of MS, i.e., in children who are below the age of 10 years, has a frequency rate around 0.2--0.7 % \[[@CR3]\], while the youngest patient diagnosed with MS was only 2 years old \[[@CR2]\]. The sex ratio varies depending on the age, which could indicate that sex hormones play an important role in the pathogenesis of MS \[[@CR17]\]. In early onset MS, the male to female ratio is almost 0.8--1. Following the growth and the development of children, the ratio increases to 1:2 after the age of 10 years \[[@CR3]\]. A positive family history has been shown in 6--20 % of children with MS \[[@CR3]\].

Etiology {#Sec2}
========

The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial disease \[[@CR18]\]. Although more than 200 genes may impact the occurrence of MS, the most significant genetic factors contributing to the development of MS are changes in the human leukocyte antigen (HLA) DRB 1 gene \[[@CR19]\]. In addition to the genetic background, the development of MS is also associated with Epstein-Barr virus (EBV) infection \[[@CR20]\], low vitamin D levels \[[@CR21]\], and smoking \[[@CR22]\]. After contact with infectious agents, the immune system can activate autoreactive, circulating cluster of differentiation 4+ (CD4+) T lymphocytes. These cells may later differentiate into T helper (Th17) with the help of interleukin 23 (IL-23), which regulates the production of IL-17. The active cell can pass through the blood--brain barrier (BBB) and reacts with autoantigens, myelin antigens, or oligodendrocytes through the mechanism of molecular mimicry \[[@CR23]\]. Th17 cells lead to the inflammation within the central nervous system (CNS), followed by migration of other T cells through the BBB, and subsequent activation of macrophages. The production of pro-inflammatory cytokines during this immunological response damages myelin and oligodendrocytes, causing plaques of inflammatory demyelination, a hallmark of this disease \[[@CR23], [@CR24]\].

The course of MS is variable, but it represents probably one of the most detailed descriptions of all autoimmune disorders, ranging from a benign type of MS (minimal disability after 15 years of disease) to malignant forms of MS (severe disability or death after a few months) \[[@CR25]\]. The various courses of MS are based on its clinical characteristics. Clinical events that characterize MS are relapse and/or progression. Relapses are defined as the occurrence, recurrence, or aggravation of neurological symptoms that last more than 24 h and occur at least 30 days after a previous attack. Between these relapses, neurological status may normalize or there may be still neurological sequelae \[[@CR26]\]. Progression is characterized by the continuous deterioration in the past 6 months \[[@CR27]\].

The clinical symptoms of the first attack, which last longer than 24 h and for which the differential diagnosis is assumed to be inflammatory demyelination with no evident signs of encephalopathy, is called a clinically isolated syndrome (CIS) \[[@CR28]\]. According to some studies, 30--75 % of patients with CIS will progress to MS \[[@CR29], [@CR30]\]. The acquired demyelinating syndromes in the pediatric population were classified and defined in 2007 \[[@CR31]\], and then updated in 2013 \[[@CR26]\] by an international consensus group. In addition to CIS, a radiological isolated syndrome (RIS) was described in recent years, which indicate MRI changes that correspond to findings present in demyelinating diseases, but these changes do not correlate with clinical findings. According to some studies, approximately 20 % of these patients will develop MS within the next 5 years \[[@CR32]\]. The course of the disease leads to the development of brain atrophy and thus, loss of brain volume. In adults with MS, both global and regional brain atrophy develops gradually \[[@CR33]\], as opposed to the pediatric MS, where most commonly regional brain atrophy develops \[[@CR34]\] associated with cognitive and physical disabilities \[[@CR35]\]. The analysis of cerebrospinal fluid in patients with pediatric MS can show negative oligoclonal bands in the beginning of the disease, but later they can be detected in over 90 % of the cases \[[@CR1]\]. The presence oligoclonal bands increases the risk of MS, but it is not exclusively specific for MS \[[@CR1], [@CR3]\].

The disease in children almost always presents in the relapsing-remittent form (RR) (85.7 % to even 100 % of cases) and the majority of these patients fully recover from the initial attack \[[@CR2], [@CR36]\]. Patients with RR MS, despite the growth of the degree of disability, are at no greater risk of a disease progression to the secondary progressive form \[[@CR37]\]. In the pediatric population, the rate of recurrence in the first 3 years of the disease is higher than in adults \[[@CR2]\]. Although the pediatric population has a higher number of relapses compared to adults, children also have faster recovery and slower disease progression when compared to adults \[[@CR1]\]. The latest diagnostic techniques allow identification of the disease even in very young patients \[[@CR38]\]. As in adults, patients in the pediatric age must exhibit at least two clinical demyelinating events, separated by at least 30 days, to be able to establish a diagnosis of MS. It is also important to exclude all other differential diagnostic causes which may correspond to the clinical picture \[[@CR1]\]. The most common diseases that must be taken into account before establishing a definitive diagnosis of MS are presented in Fig. [1](#Fig1){ref-type="fig"} \[[@CR1], [@CR39], [@CR40]\].Fig. 1Differential diagnosis of multiple sclerosis

One of the main characteristics, a must for the diagnosis of MS, is the dissemination in space and time \[[@CR1]\]. The diagnosis of MS in the pediatric population can be based on the revised McDonald's diagnostic criteria, but these criteria are not recommended to use in children younger than 12 years of age \[[@CR1]\]. Consensus about the proposed definitions and diagnostic criteria for pediatric multiple sclerosis and related disorders was published in 2007 \[[@CR31]\] and was later updated in 2013 \[[@CR26]\]. To meet the requirements for the diagnosis, one should satisfy the following criteria, according to Krupp et al. \[[@CR26], [@CR41]\], Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Diagnostic criteria for adult and pediatric MS \[magnetic resonance imaging (MRI), central nervous system (CNS), acute disseminated encephalomyelitis (ADEM), dissemination in space (DIS), dissemination in time (DIT)\]

Finally, the use of MRI as a diagnostic tool has a high sensitivity in the detection of the disease activity in both adults and in children. At the beginning of the disease, children can have multiple lesions on the MRI as compared to adults, especially in the cerebellum and brainstem \[[@CR42]\]. Moreover, MRI findings are often correlated with the clinical picture and the degree of disability \[[@CR17]\].

Treatment of Pediatric MS {#Sec3}
=========================

The therapy of pediatric MS involves treatment of relapses, and immunomodulatory and symptomatic treatment. The treatment of children with MS has to be multidisciplinary and has to include pediatric neurologists, ophthalmologists, psychologists, physiotherapists, and if necessary, pediatric psychiatrist and pharmacologist. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Immunomodulatory Therapy {#Sec4}
------------------------

The basis of MS therapy should rely on drugs that are able to modify the course of the disease, i.e. immunomodulatory drugs. These drugs can be subdivided into two general categories: first-line immunomodulatory therapy and second-line immunomodulatory therapy (Table [1](#Tab1){ref-type="table"}). According to the current recommendations, pediatric patients with MS should be treated with these disease-modifying drugs, as early as possible \[[@CR43]\].Table 1First-line and second-line immunomodulatory therapy (intramuscularly---i.m.; subcutaneously---s.c.; intravenously---i.v.; per os---p.o.)DoseMode of applicationDosing regimenReferencesFirst-line immunomodulatory therapy Interferon beta-1a30 µgi.m.Once a week\[[@CR43], [@CR44]\]22--44 µgs.c.Three times a week\[[@CR43], [@CR44]\] Interferon beta-1b250 µgs.c.Every other day\[[@CR44]\] Glatiramer acetate20 mgs.c.Once a day\[[@CR44]\]Second-line immunomodulatory therapy Natalizumab3--5 mg/kgi.v.Once a month\[[@CR2], [@CR43], [@CR45]\] MitoxantroneIn a dose of 10--20 mg---up to a total dose of 200 mgi.v.Once every 3 months\[[@CR46]\] Fingolimod0.5 mgp.o.Once a day\[[@CR2]\] Teriflunomide7 and 14 mgp.o.Once a day\[[@CR2]\] Azathioprine2.5--3 mg/kgp.o.Once a day\[[@CR46]\] Rituximab500--1000 mgi.v.Every 6--12 months\[[@CR2], [@CR46]\] Dimethyl fumarateInitial dose 120 mg, therapeutic dose 240 mgp.o.Twice daily\[[@CR47], [@CR48]\] Daclizumab150 mgs.c.Once a month\[[@CR49], [@CR50]\]

First-Line Immunomodulatory Therapy {#Sec5}
-----------------------------------

Drugs that modify the disease and can be given to children older than 12 years are interferon beta-1a (Avonex^®^, Rebif^®^), interferon beta-1b (Betaferon^®^), and glatiramer acetate (Copaxone^®^). These drugs have been approved by the European Medicines Agency (EMA). Avonex^®^ is given once a week in a dose of 30 µg i.m., while Rebif^®^ is administered three times a week in a dose of 22--44 µg, s.c. Interferon beta-1b is given every other day in a dose of 250 µg s.c. and glatiramer acetate in a dose of 20 mg also s.c. \[[@CR44]\]. These drugs can reduce the number of relapses in adults up to 30 % \[[@CR2], [@CR51]\]. Efficiency, effectiveness, and side effects of these drugs are based on data from clinical studies, but it is necessary to note that some studies are still ongoing \[[@CR2]\]. All of these drugs have shown significant therapeutic effectiveness by reducing the frequency and severity of clinical relapses and disease activity as shown by MRI of the brain, and are also able to reduce the degree of disability \[[@CR44]\]. These drugs are well tolerated, but must be administered i.m. or s.c., which can be a problem for use in pediatric patients \[[@CR2], [@CR44], [@CR51]\].

Interferon acts through specific receptors to regulate signaling cascades. Its effect is mediated through the inhibition of autoreactive T cell inhibition of pro-inflammatory cytokines, reduction of lymphocyte migration, and induction of anti-inflammatory mediators \[[@CR2]\]. The most common side effects are flu-like symptoms, injection skin reaction, headache, myalgia, nausea, fatigue, increased liver enzyme values, and thyroid dysfunction \[[@CR44]\]. In patients who have developed flu-like symptoms, ibuprofen or paracetamol can be used. The use of these drugs requires monitoring of hematological parameters and liver enzyme values each month during the first 6 months and then once every 3 months. Occasionally, it is also necessary to check thyroid function \[[@CR52]\]. Based on published data observed side effects of s.c. administration of interferon beta-1a, in patients who were older than 12 and even in patients who were younger than 12 years, were: injection-site reactions, influenza-like symptoms, hepatic disorders, blood cell disorders (e.g. thrombocytopenia, leucopenia, anemia), elevations in alanine aminotransferase and aspartate aminotransferase concentrations, allergic reactions (e.g. rash, urticaria, anaphylaxis), epilepsy and convulsive disorders, thyroid dysfunction, autoimmune diseases, bone/epiphyseal and cartilage disorders, and serious infections \[[@CR43]\].

Glatiramer acetate is relatively well-tolerated, even during long-term use \[[@CR44]\]. Glatiramer acetate achieves its effect by inhibiting specific effector T-lymphocytes and influencing antigen-presenting cells and suppressor T-lymphocytes \[[@CR2]\]. Some studies suggest that glatiramer acetate may cause a transient flushing-like reaction associated with tachycardia \[[@CR52]\]. Recent studies on the use of glatiramer acetate in the pediatric population are scarce.

Second-Line Immunomodulatory Therapy {#Sec6}
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Second-line drugs are available only as a part of ongoing clinical studies. Natalizumab (Tysabri^®^) is a monoclonal antibody. The drug targets α4β1-integrin and blocks migration of T- and B-lymphocytes across the blood--brain barrier \[[@CR2]\]. It is given once a month by intravenous infusion using a dose of 300 mg \[[@CR46]\] or 3--5 mg/kg \[[@CR2]\]. Because of its high efficacy, it is able to reduce the activity of MS and its progression. Application of natalizumab is contraindicated in the pediatric population; however, according to some clinical trials, natalizumab was able to significantly decrease the disease activity and had fewer serious side effects in pediatric patients as compared to adults \[[@CR53]\]. Although it reduces the number of relapses by 68 % \[[@CR46]\], this drug has a high risk of serious side effects, such as progressive multifocal leukoencephalopathy, hypersensitivity, and infections \[[@CR2], [@CR53], [@CR54]\].

Mitoxantrone (Novantrone^®^) is administered as an intravenous infusion once every 3 months using a dose of 10--20 mg with a maximal dose of 200 mg \[[@CR46]\]. It is used in patients with an aggressive form of disease or in patients with severe cases of relapse remitting MS and secondary progressive MS \[[@CR55]\]. The most common side effects of this drug are cardiotoxicity, leukopenia, nausea, infections, alopecia, fatigue, and amenorrhea \[[@CR46], [@CR55]\].

Fingolimod (Gylenia^®^) tablets (0.5 mg) are taken once daily orally which is a great advantage over drugs that have to be administered i.m or s.c.. The drug targets the sphingosine-1-phosphate receptor \[[@CR2]\]. It has been used in adults since 2010, and its application in pediatric patients is being tested through clinical studies. Fingolimod has a higher efficcacy than first-line drugs, but is also associated with a risk of serious adverse effects. The most common side effects include abnormal heart rhythm after the first dose of drug and macular edema \[[@CR56]\].

Teriflunomide (Aubagio^®^) has been accepted as yet another drug that can be given orally. Tablets of 7 and 14 mg are administered once a day. Its safety profile is favorable and most common unwanted effects are alopecia and hepatotoxicity \[[@CR2]\]. The results of the studies in pediatric patients are yet to be expected in the future.

Azathioprine is an immunosuppressive drug used in adults. The drug antagonizes purine metabolism and it is given orally in a dose of 2.5--3 mg/kg/day. The most common side effects are skin rashes, gastrointestinal symptoms, cytopenia, and liver toxicity. There is also a risk of cancer occurrence \[[@CR46]\].

Cyclophosphamide (Cytoxan^®^) is an immunosuppressive drug with cytotoxic effects. For the time being it is not given in the pediatric population for this indication. The most common side effects of this drug are vomiting, amenorrhea, transient alopecia and osteoporosis. Regular control in patients on cyclophosphamide therapy is necessary in order to prevent a possible development of amenorrhea, sterility, infections and malignancies \[[@CR2], [@CR46]\].

Rituximab (Rituxan^®^) is chimeric monoclonal immunoglobulin G1 (IgG1)---kappa antibody that targets the CD20 receptor on activated B lymphocytes. It has been shown to reduce relapses in adolescents. A few cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients with systemic lupus erythematosus who were treated with this drug, which represents a serious and difficult side effect of this drug \[[@CR2], [@CR46]\]. So far there are only few studies on the use of rituximab in pediatric patients with MS, which is why the recommendations for its administration do not exist, and therefore require further studies \[[@CR57]\].

The mechanism of action of dimethyl fumarate (Tecfidera^®^) is still not fully known, but the drug has been shown to reduce cytokine production, lymphocyte count and result in reduction of migratory activity of immune cells through the BBB \[[@CR58]\]. Monomethyl fumarate is the active metabolite of this drug \[[@CR59]\]. Dimethyl fumarate is administered orally using a dose of 120 mg and 240 mg and is intended for the treatment of patients with relapsing forms of MS \[[@CR47]\]. The most common and significant side-effects of dimethyl fumarate are itching, redness, nausea, vomiting, abdominal pain and diarrhea, lymphopenia, PML, allergic reaction, hives, rash, itching, hoarseness, and vision problems.

Daclizumab (Zinbryta^®^) is administered once a month in a dose of 150 mg, s.c. Daclizumab is a monoclonal humanized antibody that selectively binds to the IL-2 receptor alpha-chain. The effect of daclizumab showed a reduced relapse rate and fewer new lesions on MRI \[[@CR49], [@CR50]\]. The most common and significant side-effects of daclizumab are serious infections, gastrointestinal disorders, depression, liver toxicity and elevations of liver enzymes, serious cutaneous events. So far there is only one study on the use of daclizumab in pediatric patients with MS. It reduces clinical and MRI disease activity in pediatric patients. Side-effects were mild \[[@CR49], [@CR50]\].

Treatment of Relapses {#Sec7}
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Treatment of relapses involves the use of high intravenous doses of corticosteroids such as the administration of methylprednisolone in doses of 20--30 mg/kg and up to 1000 mg per day once a day in the morning. This treatment should last 3--5 days and needs to be supported by gastroprotective medications. Unlike in adults, pediatric neurologists can decide if there is a need for a short term extension of the corticosteroid treatment \[[@CR1]\]. The use of corticosteroids this way reduces the number of side-effects to a minimum. Side effects of corticosteroid use in children are: mood disorders, insomnia, hypertension, and hyperglycemia \[[@CR3]\]. If the administration of corticosteroids does not result in improvement of clinical findings, it can be replaced by a 5-day administration of intravenous immunoglobulins using a dose of 0.4 g/kg/day. In addition, plasmapheresis is another therapeutic option if the previous forms of therapy did not result in satisfactory results \[[@CR1]\].

Treatment of Specific Symptoms {#Sec8}
------------------------------

Symptomatic therapy should be directed towards eliminating specific symptoms, which may occur in the course of the disease. The most common symptoms that occur in children are pain, anxiety, depression, fatigue, stiffness (spasm), interference with urination, and sexual dysfunction. If the symptoms of anxiety and depression are noticed, it is necessary to immediately include a pediatric or adolescent psychiatrist in order to prevent progression. Pain that occurs in MS patients is of neuropathic origin and should be treated according to the recommendations for the treatment of neuropathic pain (tricyclic antidepressants, gabapentin and pregabalin, 5% lidocaine, and tramadol) \[[@CR60]\].

Conclusion {#Sec9}
==========

Pediatric MS still represents a major diagnostic and therapeutic problem. Early administration of immunomodulatory therapy is beneficial in adults, while more studies are needed to prove their effectiveness in pediatric populations. Therefore, better knowledge of both the etiology and pathogenesis of pediatric MS is of great importance in search of the correct treatment.
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